Preliminary report on the use of subcutaneous immunoglobulin in severe inflammatory myopathies

摘要

We report our experience with subcutaneous immunoglobulins (SCIg) in two subjects with chronic refractory inflammatory myopathies. The first was a 19-year-old male with ocular myositis refractory to previous different immunosuppressive therapies and with steroid-dependency. The second subjects was a 52-year-old woman with monocyclic chronic dermatomyositis already successfully treated with prednisone, cyclosporine A and intravenous immunoglobulin (IVIG) with difficult venous access. SCIg (Vivaglobin~R; CSL Behring) was administered by a programmable pump. In this first six-month period of treatment, no relapse of the disease occurred. Both patients showed a clinical response and reported a good tolerance of the treatment. Our preliminary experience demonstrates the administration of SCIg is safe and beneficial in inflammatory myopathies.